7261-97-4
7261-97-4
Chemical Structure
Dantrolene
Synonym(s): F 368
- CAS No.: 7261-97-4
- Formula:C14H10N4O5
- Molecular Weight:314.26
IUPAC Name: (E)-1-(((5-(4-nitrophenyl)furan-2-yl)methylene)amino)imidazolidine-2,4-dione
InChIKey: OZOMQRBLCMDCEG-VIZOYTHASA-N
SMILES: O=C1NC(CN1/N=C/C2=CC=C(C3=CC=C([N+]([O-])=O)C=C3)O2)=O
Biological Activity: Dantrolene is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene is also a calcium channel protein inhibitor. Dantrolene inhibits the release of Ca2+ from RyR1 and RyR3, which can be beneficial in a variety of pathologies caused by disruptions in calcium homeostasis (e.g., stroke, ischemia/reperfusion injury, and neurodegenerative diseases). Dantrolene offers relief of muscle spasms, malignant hyperthermia, and antitoxic, antipyretic, and anti-inflammatory properties[1][2][3][4][5][6][7][8][9][10][11].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Dantrolene | 99.93% | Dantrolene is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene is also a calcium channel protein inhibitor. Dantrolene inhibits the release of Ca2+ from RyR1 and RyR3, which can be beneficial in a variety of pathologies caused by disruptions in calcium homeostasis (e.g., stroke, ischemia/reperfusion injury, and neurodegenerative diseases). Dantrolene offers relief of muscle spasms, malignant hyperthermia, and antitoxic, antipyretic, and anti-inflammatory properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dantrolene (Standard) | ≥98% | Dantrolene (Standard) is the analytical standard of Dantrolene. This product is intended for research and analytical applications. Dantrolene is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene is a ryanodine receptor (RyR) antagonist and Ca2+ signaling stabilizer. Dantrolene is a direct-acting skeletal muscle relaxant. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Azumolene sodium | Azumolene sodium (EU4093) is an analog of Dantrolene (HY-12542) that inhibits malignant hyperthermia (MH) syndrome and intracellular Ca2+ homeostasis failure caused by Halothane (HY-B1010)/Succinylcholine. Azumolene sodium (0.5-2.0 mg/kg) reduces [Ca2+]i (from 207 nM to 38 nM) in MH-susceptible skeletal muscle following intramuscular injection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Azumolene | 99.11% | Azumolene (EU4093 free base), a Dantrolene analog, is a muscle relaxant. Azumolene is a ryanodine receptor (RyR) modulator and inhibits the calcium-release through ryanodine receptor. Azumolene can be used for malignant hyperthermia research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dantrolene-13C3 | 99.0% | Dantrolene-13C3 is the 13C3 labeled Dantrolene. Dantrolene (F368), a muscle relaxant, non-competitively inhibits human erythrocyte glutathione reductase. Ki and IC50 values are 111.6 μM and 52.3 μM, respectively. Dantrolene is a ryanodine receptor antagonist and Ca2+ signaling stabilizer. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dantrolene sodium | 99.79% | Dantrolene sodium is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene sodium is also a calcium channel protein inhibitor. Dantrolene sodium inhibits the release of Ca2+ from RyR1 and RyR3, which can be beneficial in a variety of pathologies caused by disruptions in calcium homeostasis (e.g., stroke, ischemia/reperfusion injury, and neurodegenerative diseases). Dantrolene sodium offers relief of muscle spasms, malignant hyperthermia, and antitoxic, antipyretic, and anti-inflammatory properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
F8-S43-S3 | F8-S43-S3 is an inhibitor of SARS-CoV-2 main protease, with an IC50 of 9.69 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nitrofurantoin sodium | 99.73% | Nitrofurantoin sodium is a potent and orally active antibacterial agent. Nitrofurantoin sodium acts as an antibiotic. Nitrofurantoin sodium can be used for the study of urinary tract infections (UTIs), including cystitis and kidney infections. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nitrofurantoin (Standard) | 99.74% | Nitrofurantoin (Standard) is the analytical standard of Nitrofurantoin. This product is intended for research and analytical applications. Nitrofurantoin is a potent and orally active broad-spectrum beta-lactamase antimicrobial agent. Nitrofurantoin acts as an antibiotic and can be used for the study of urinary tract infections (UTIs), including cystitis and kidney infections. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nitrofurantoin-13C3 | Nitrofurantoin-13C3 is the 13C labeled Nitrofurantoin (HY-A0090). Nitrofurantoin is a potent and orally active broad-spectrum beta-lactamase antimicrobial agent. Nitrofurantoin acts as an antibiotic and can be used for the study of urinary tract infections (UTIs), including cystitis and kidney infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-(4-Nitrophenyl)furan-2-carbaldehyde (Standard) | ≥98% | 5-(4-Nitrophenyl)furan-2-carbaldehyde (Standard) is the analytical standard of 5-(4-Nitrophenyl)furan-2-carbaldehyde. This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dantrolene-d4 | Dantrolene-d4 is deuterium labeled Dantrolene. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhang W, et al. Neuroprotective effects of dantrolene in neurodegenerative disease: Role of inhibition of pathological inflammation. J Anesth Transl Med. 2024 Jun;3(2):27-35. [Content Brief]
- [2]. Choi RH, et al. Dantrolene requires Mg2+ to arrest malignant hyperthermia. Proc Natl Acad Sci U S A. 2017 May 2;114(18):4811-4815. [Content Brief]
- [3]. Wang Y, et al. Dantrolene Ameliorates Impaired Neurogenesis and Synaptogenesis in Induced Pluripotent Stem Cell Lines Derived from Patients with Alzheimer's Disease. Anesthesiology. 2020 May;132(5):1062-1079. [Content Brief]
- [4]. Zardast M, et al. Evaluation of the Effectiveness of Dantrolene against Digoxininduced Cardiotoxicity in Adult Rats. Cardiovasc Hematol Agents Med Chem. 2023;22(1):60-65. [Content Brief]
- [5]. Osipchuk NC, et al. Modulation of Ryanodine Receptors Activity Alters the Course of Experimental Autoimmune Encephalomyelitis in Mice. Front Physiol. 2021 Dec 17;12:770820. [Content Brief]
- [6]. Shi Y, et al. Intranasal Dantrolene as a Disease-Modifying Drug in Alzheimer 5XFAD Mice. J Alzheimers Dis. 2020;76(4):1375-1389. [Content Brief]
- [7]. Xu SY, et al. Dantrolene enhances the protective effect of hypothermia on cerebral cortex neurons. Neural Regen Res. 2015 Aug;10(8):1279-85. [Content Brief]
- [8]. F Zhao, et al. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem. 2001 Apr 27;276(17):13810-6. [Content Brief]
- [9]. Christopher B Sylvester, et al. Dantrolene inhibits lysophosphatidylcholine-induced valve interstitial cell calcific nodule formation via blockade of the ryanodine receptor. Front Cardiovasc Med. 2023 Mar 30:10:1112965. [Content Brief]
- [10]. Xi Chen, et al. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model. Mol Neurodegener. 2011 Nov 25;6:81. [Content Brief]
- [11]. Büyükokuroğlu ME. Anti-inflammatory and antinociceptive properties of Dantrolene in rats and mice. Pharmacol Res. 2002 Jun;45(6):455-60. [Content Brief]
